Live
Event: 12/1/2023
Activity
Launch Date: 06/24/2024
Activity
Expiration Date: 06/24/2027
Overview
There are many dilemmas that medical
professionals in epilepsy grapple with when conducting genetic testing for
their patients. Once an opportunity to do genetic testing is identified, there
are many more questions that arise. Knowing the right time to test,
understanding the results of a test, discussing results with patients, and
answering questions from families make the process of doing genetic testing
time-consuming and challenging.
This session addresses a number of dilemmas
related to genetic testing, including clinical concerns, clinical care
scenarios, transition to adult care, and treatment implications. This is
addressed through a series of presentations and interactive activities. We
share perspectives from physicians, researchers, and genetic counselors, plus
people living with epilepsy and their family members, about how to address
these dilemmas.
Learning Objectives
Following participation in this activity,
participants will be able to:
- Evaluate the challenges of genetic testing for people with epilepsy
- Better manage common dilemmas related to genetic testing in the clinical setting
- Make informed treatment decisions based on genetic testing results
Chair
Anup Patel, MD, FAAN, FAES;
Sarah Kelley, MD, FAES
Program
Introduction | M. Scott Perry, MD, FAES
Patient & Caregiver Dilemmas: What I Would
Like Clinicians to Know | Tristin West
Clinical Dilemmas Related to Genetic Testing |
Christa Habela, MD PhD and Krista Schatz, MS, CGC
Dilemmas in Clinical Care Scenarios | Dalila
Lewis, MD, FAAP
Genetic Testing in the Transition to Adult Care
| Danielle Andrade, MD, MSc, FRCPC
Treatment Dilemmas | Scott Demarest, MD
Target Audience
Advanced Practice Providers (APPs), Advocates,
Clinicians, Fellows/Trainees, Nurses, Pharmacists, Scientists/Researchers
Session Content Includes
Diversity, Equity, and Inclusion (DEI), Patient
Perspective, Pediatric
Planning Committee, Faculty, Reviewers’
Disclosures of Financial Relationships
In accordance with the ACCME Standards for
Integrity and Independence in Accredited Continuing Education, the AES requires
that any person who is in a position to control content of a CME activity must
disclose all relevant financial relationships that they have with an ineligible
company. Unless otherwise indicated (*), none of the planners or faculty of
this activity have any financial relationships to disclose. All relevant
financial relationships with ineligible companies have been mitigated. The following
individuals contributed to this activity’s content.
CME Reviewer
Ashley Thomas, MD
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society
to ensure balance, independence, objectivity and scientific rigor. All persons
involved in the selection, development and presentation of content are required
to disclose any real or apparent conflicts of interest. In accordance with the
ACCME Standards of Integrity and Independence in Accredited Continuing
Education, the AES implemented the mechanisms of prospective peer review of
this CME activity, to identify and resolve any conflicts. Additionally, the content
of this activity is based on the best available evidence.
Accreditation
The American Epilepsy Society is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
For more information regarding contact hours,
please call American Epilepsy Society 312.883.3800.
Credit
Designation
The American Epilepsy Society designates this live
activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.
CME and CE Certificates
To receive credit for your participation in this
activity, please complete the evaluation survey provided at the conclusion of
the activity.
Unapproved
Use Disclosure
The American Epilepsy Society requires CME authors
to disclose to learners when products or procedures being discussed are
off-label, unlabeled, experimental, and/or investigational (not FDA approved);
and any limitations on the information that is presented, such as data that are
preliminary or that represent ongoing research, interim analyses, and/or
unsupported opinion. This information is intended solely for continuing medical
education and is not intended to promote off-label use of these medications. If
you have questions, contact the medical affairs department of the manufacturer
for the most recent prescribing information. Information about pharmaceutical
agents/devices that is outside of U.S. Food and Drug Administration approved
labeling may be contained in this activity.
Disclaimer
This CME activity is for educational purposes only
and does not constitute the opinion or endorsement of, or promotion by, the
American Epilepsy Society. Reasonable efforts have been taken to present
educational subject matter in a balanced, unbiased fashion, and in compliance
with regulatory requirements. However, each activity participant must always
use his or her own personal and professional judgment when considering further
application of this information, particularly as it may relate to patient diagnostic
or treatment decisions including, without limitation, FDA-approved uses and any
off-label, investigational and/or experimental uses.